Phage-displayed antibody libraries and uses thereof

Disclosed herein are phage-displayed single-chain variable fragment (scFv) libraries, which comprised a plurality of scFvs with a specific sequence in each CDR. The present scFv libraries could be used to efficiently produce different antibodies with high binding affinity to H1 hemagglutinin of influenza virus. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

Immunoconjugate and uses thereof

Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.

PHAGE-DISPLAYED SINGLE-CHAIN VARIABLE FRAGMENT LIBRARIES AND USES THEREOF

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized in having a specific CS combination and a specific sequence in each CDR. The present scFv library is useful in efficiently producing different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications. 1. A phage-displayed single-chain variable fragment (scFv) library comprising a plurality of phage-displayed scFvs , wherein each of the plurality of phage-displayed scFvs comprises a first light chain complementarity determining region (CDR-L1) , a second light chain CDR (CDR-L2) , a third light chain CDR (CDR-L3) , a first heavy chain CDR (CDR-H1) , a second heavy chain CDR (CDR-H2) , and a third heavy chain CDR (CDR-H3) , whereinthe CDR-L1 is encoded by a first coding sequence comprising the nucleic acid sequence of SEQ ID NO: 8 or 10;the CDR-L2 is encoded by a second coding sequence comprising the nucleic acid sequence of SEQ ID NO: 12, 14, 16 or 18;the CDR-L3 is encoded by a third coding sequence comprising the nucleic acid sequence of SEQ ID NO: 20 or 22;the CDR-H1 is encoded by a fourth coding sequence comprising the nucleic acid sequence of SEQ ID NO: 24, 26, 28, 30, 32, 34, 36 or 38;the CDR-H2 is encoded by a fifth coding sequence comprising the nucleic acid sequence of SEQ ID NO: 40 or 42; andthe CDR-H3 is encoded by a sixth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 45-46, 52-56, 60-62 67-70, 76-80, 91-100, 116-130 and 152-172.2. The phage-displayed scFv library of claim 1 , whereinthe first coding sequence has the nucleic acid sequence of SEQ ID NO: 7 or 9;the second coding sequence has the nucleic acid sequence of SEQ ID NO: 11, 13, 15 or 17;the third coding sequence has the ...

Method for high-throughput screening of neutralizing antibodies, neutralizing antibodies produced therefrom, and uses thereof

Disclosed herein are methods for high-throughput screening of a virus-specific neutralizing antibody. According to certain embodiments of the present disclosure, the virus is an influenza virus. Also disclosed herein are the antibodies selected by the high-throughput screening method, and the uses thereof in the prophylaxis and/or treatment of viral infection.

GLYCAN ARRAYS FOR HIGH THROUGHPUT SCREENING OF VIRUSES

Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed. Sandwich assays using gold nanoparticles conjugated to phage particles comprising influenza virus-specific antibodies for detecting multiple serotypes using a single reaction are provided. Plurality of glycans directed to specific target HA of influenza virus comprises the array. Detector molecules comprising noble metals conjugated to (a) phage display particles expressing antibodies against hemagglutinin and (b) neuraminidase binding agents are disclosed. 1. A method for detecting at least one influenza serotype in a sample , the method comprising the steps of:a) providing a substrate having at least one type of glycan capture probe bound at a discrete location on the substrate, wherein the capture probe can bind to a specific influenza serotype target;b) providing at least one type of nanoparticle probe conjugated to a detector moiety, wherein the detector moiety binds to the specific influenza serotype;c) contacting the substrate with the sample and the nanoparticle probe under conditions suitable for the binding of the glycan capture probe to the specific influenza serotype and the binding of the nanoparticle probe to the specific influenza serotype to form a complex at the discrete location on the substrate; andd) detecting the presence or absence of the complex wherein the presence or absence of the complex is indicative of the presence or absence of the specific influenza serotype in the sample.2. The method of claim 1 , wherein the influenza serotype is selected from the group consisting of influenza A claim 1 , influenza B claim 1 , influenza A serotypes H1N1 claim 1 , H2N2 claim 1 , H3N1 claim 1 , H3N2 claim 1 , H5N1 claim 1 , H7N7 claim 1 , H1N2 claim 1 , H9N2 claim 1 , H7N2 claim 1 , H7N3 claim 1 , and H10N7.3. The method of or claim ...

Recombinant antibody and uses thereof

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

Phage-displayed single-chain variable fragment libraries and uses thereof

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized in having a specific CS combination and a specific sequence in each CDR. The present scFv library is useful in efficiently producing different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

Phage displaying system expressing single chain antibody

Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries. Further disclosed are methods for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and methods for producing a disulfide-stabilized single chain antibody and non-fusion form thereof.

Glycan arrays for high throughput screening of viruses

Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed. Sandwich assays using gold nanoparticles conjugated to phage particles comprising influenza virus-specific antibodies for detecting multiple serotypes using a single reaction are provided. Plurality of glycans directed to specific target HA of influenza virus comprises the array. Detector molecules comprising noble metals conjugated to (a) phage display particles expressing antibodies against hemagglutinin and (b) neuraminidase binding agents are disclosed.

Phage-displayed single-chain variable fragment library

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

Phage displaying system expressing single chain antibody

Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries. Further disclosed are methods for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and methods for producing a disulfide-stabilized single chain antibody and non-fusion form thereof.

PHAGE DISPLAYING SYSTEM EXPRESSING SINGLE CHAIN ANTIBODY

Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries. Further disclosed are methods for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and methods for producing a disulfide-stabilized single chain antibody and non-fusion form thereof. 19-. (canceled)10. An isolated nucleic acid , comprisinga first nucleotide sequence encoding a signal peptide, anda second nucleotide sequence encoding a single chain antibody capable of forming an interface disulfide bond, the second nucleotide sequence being located 3′ downstream to the first nucleotide, wherein the signal peptide has the amino acid sequence of:{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10, '(a) VKKLLXXXXXXXXXXAAQPAMAHHHHHHGH (SEQ ID NO:596), in which Xis A, C, F, G, I, L, M, P, Q, S, V, W, or Y; Xis A, D, F, G, H, I, L, M, N, P, S, T, V, or W; Xis A, F, G, L, M, P, Q, R, S, T, V, or W; Xis A, F, G, H, I, L, M, P, Q, R, S, T, V, W, or Y; Xis A, C, D, F, G, H, I, L, M, P, Q, R, S, T, V, W, or Y; Xis A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; Xis A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; Xis A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; Xis A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and Xis A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y;'}{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10, '(b) VKKLLFAIPLXXXXXXXXXXMAHHHHHHGH (SEQ ID NO:597), in which XA, C, F, G, H, I, L, M, N, P, Q, S, T, V, W, or Y; Xis A, C, D, F, G, H, I, L, M, P, Q, R, S, T, V, W, or Y; Xis A, C, D, F, G, H, I, L, M, N, P, Q, R, S ...

High-throughput screening of functional antibody fragments, immunoconjugate comprising the same, and adaptor-drug conjugate for screening

Disclosed herein are methods for high-throughput screening of a functional antibody fragment for an immunoconjugate that targets a protein antigen. The method combines a phage-displayed synthetic antibody library and high-throughput cytotoxicity screening of non-covalently assembled immunotoxins or cytotoxic drug to identify highly functional synthetic antibody fragments for delivering toxin payloads.

PHAGE DISPLAYING SYSTEM EXPRESSING SINGLE CHAIN ANTIBODY

Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries. Further disclosed are methods for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and methods for producing a disulfide-stabilized single chain antibody and non-fusion form thereof. 1. An isolated nucleic acid , comprising:a first nucleotide sequence encoding a signal peptide, and{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10, 'a second nucleotide sequence encoding a single chain antibody capable of forming an interface disulfide bond, the second nucleotide sequence being located 3′ downstream to the first nucleotide, wherein the signal peptide has the amino acid sequence of VKKLLFAIPLVVPFYXXXXXXXXXXHHHGH (SEQ ID NO:598), in which Xis A, C, D, F, G, I, L, M, N, P, Q, R, S, T, V, or Y; Xis A, C, D, F, G, H, K, L, N, P, Q, R, S, T, V, W, or Y; Xis A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; Xis A, C, D, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; Xis A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; Xis A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; Xis A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; Xis A, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; Xis A, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and Xis A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y.'}2. The nucleic acid of claim 1 , further comprising a third nucleotide encoding a phage coat protein claim 1 , the third nucleotide sequence being located 3′ downstream to the second nucleotide sequence.3. The nucleic acid of claim 1 , wherein the nucleic acid is an expression vector for expression a ...

PHAGE DISPLAYING SYSTEM EXPRESSING SINGLE CHAIN ANTIBODY

Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries. Further disclosed are methods for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and methods for producing a disulfide-stabilized single chain antibody and non-fusion form thereof.

A phage-displayed single-chain variable fragment library

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

Computational method for predicting functional sites of biological molecules

In a general aspect, a method for inferring one or more biomolecule-to-biomolecule interaction sites includes receiving data representative of a plurality of prediction models. Each prediction model is associated with a different atom type of a plurality of atom types and characterizes biomolecule-to-biomolecule interaction site specific patterns common to a plurality of three dimensional probability density maps. Each three dimensional probability density map is associated with a corresponding biomolecule of a plurality of biomolecules included in a training data set and represents a probability of a non-covalent interacting atom on a surface of the corresponding biomolecule interacting with the atom type associated with the prediction model. Data representative of a query biomolecule is received, the data including one or more unknown biomolecule-to-biomolecule interaction sites. The one or more unknown biomolecule-to-biomolecule interaction sites of the query biomolecule are inferred based on the data representative of the plurality of prediction models.

Immunoconjugate and uses thereof

Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.

PHAGE-DISPLAYED ANTIBODY LIBRARIES AND USES THEREOF

Disclosed herein are phage-displayed single-chain variable fragment (scFv) libraries, which comprised a plurality of scFvs with a specific sequence in each CDR. The present scFv libraries could be used to efficiently produce different antibodies with high binding affinity to H1 hemagglutinin of influenza virus. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications. 1. A phage-displayed single-chain variable fragment (scFv) library comprising a plurality of scFvs that are expressed by a phage and exhibit binding affinity and specificity to a protein antigen , wherein each of the plurality of scFvs comprises at least one polypeptide selected from the group consisting of ,a first complementarity determining region (CDR) encoded by the nucleotide sequence of SEQ ID NO: 1,a second CDR encoded by the nucleotide sequence of SEQ ID NO: 2, anda third CDR encoded by a the nucleotide sequence of SEQ ID NO: 3.2. The phage-displayed scFv library of claim 1 , wherein the phage is a M13 phage or a T7 phage.3. The phage-displayed scFv library of claim 1 , wherein the protein antigen is a hemagglutinin of influenza virus.4. A method for selecting one phage-displayed scFv from the phage-displayed scFv library of claim 1 , wherein the phage-displayed scFv exhibits high affinity and specificity to a protein antigen claim 1 , comprising claim 1 ,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) incubating the phage-displayed scFv library of with protein antigens, wherein the phage-displayed scFv library comprises a plurality of phage-displayed scFvs;'}(b) subjecting the product of step (a) to an acid treatment thereby producing a plurality of phage-displayed scFvs, which are respectively bound to the protein antigens before the acid treatment;(c) subjecting the plurality of phage-displayed scFvs produced in the step (b) to an ...

Method for high-throughput screening of neutralizing antibodies, neutralizing antibodies produced therefrom, and uses thereof

Disclosed herein are methods for high-throughput screening of a virus-specific neutralizing antibody. According to certain embodiments of the present disclosure, the virus is an influenza virus. Also disclosed herein are the antibodies selected by the high-throughput screening method, and the uses thereof in the prophylaxis and/or treatment of viral infection.

COMPUTATIONAL METHOD FOR PREDICTING FUNCTIONAL SITES OF BIOLOGICAL MOLECULES

In a general aspect, a method for inferring one or more biomolecule-to-biomolecule interaction sites includes receiving data representative of a plurality of prediction models. Each prediction model is associated with a different atom type of a plurality of atom types and characterizes biomolecule-to-biomolecule interaction site specific patterns common to a plurality of three dimensional probability density maps. Each three dimensional probability density map is associated with a corresponding biomolecule of a plurality of biomolecules included in a training data set and represents a probability of a non-covalent interacting atom on a surface of the corresponding biomolecule interacting with the atom type associated with the prediction model. Data representative of a query biomolecule is received, the data including one or more unknown biomolecule-to-biomolecule interaction sites. The one or more unknown biomolecule-to-biomolecule interaction sites of the query biomolecule are inferred based on the data representative of the plurality of prediction models. 1. A non-transitory computer readable medium comprising instructions for inferring one or more biomolecule-to-biomolecule interaction sites , the instructions , when executed by at least one processor , comprising functionality to:receive data representative of a plurality of prediction models, each prediction model associated with a different atom type of a plurality of atom types and characterizing biomolecule-to-biomolecule interaction site specific patterns common to a plurality of three dimensional probability density maps, each three dimensional probability density map associated with a corresponding biomolecule of a plurality of biomolecules included in a training data set and representative of a probability of a non-covalent interacting atom on a surface of the corresponding biomolecule interacting with the atom type associated with the prediction model;receive data representative of a query biomolecule ...

ANTI-SIGLEC ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF

Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection. 1. An antibody or a fragment thereof for the prophylaxis or treatment of hepatitis B virus (HBV) infection , comprising ,a light chain variable region comprising the amino acid sequences of VYY, ISSAG (SEQ ID NO: 3) and QYFNFP (SEQ ID NO: 4); anda heavy chain variable region comprising the amino acid sequences of NNGW (SEQ ID NO: 5), GIGPYGGSTF (SEQ ID NO: 6), and SRFIGSYSHM (SEQ ID NO: 7)2. The antibody or a fragment thereof of claim 1 , wherein the light chain variable region comprises the amino acid sequence at least 85% identical to SEQ ID NO: 8 claim 1 , and the heavy chain variable region comprises the amino acid sequence at least 85% identical to SEQ ID NO: 9.3. The antibody or a fragment thereof of claim 2 , wherein the light chain variable region has the amino acid sequence of SEQ ID NO: 8 claim 2 , and the heavy chain variable region has the amino acid sequence of SEQ ID NO: 9.4. A method of preventing or treating HBV infection in a subject claim 1 , comprising administering to the subject an effective amount of the antibody or a fragment thereof of .5. The method of claim 4 , wherein the light chain variable region of the antibody comprises the amino acid sequence at least 85% identical to SEQ ID NO: 8 claim 4 , and the heavy chain variable region of the antibody comprises the amino acid sequence at least 85% identical to SEQ ID NO: 9.6. The method of claim 5 , wherein the light chain variable region has the amino acid sequence of SEQ ID NO: 8 claim 5 , and the heavy chain variable region has the amino acid sequence of SEQ ID NO: 9.7. The method of claim 4 , wherein the subject is a human.813-. (canceled)14. A pharmaceutical ...

Recombinant antibody and uses thereof

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

HIGH-THROUGHPUT SCREENING OF FUNCTIONAL ANTIBODY FRAGMENTS, IMMUNOCONJUGATE COMPRISING THE SAME, AND ADAPTOR-DRUG CONJUGATE FOR SCREENING

Disclosed herein are methods for high-throughput screening of a functional antibody fragment for an immunoconjugate that targets a protein antigen. The method combines a phage-displayed synthetic antibody library and high-throughput cytotoxicity screening of non-covalently assembled immunotoxins or cytotoxic drug to identify highly functional synthetic antibody fragments for delivering toxin payloads. 1. A method for high-throughput screening of a functional antibody fragment for an immunoconjugate that targets a protein antigen , comprising the steps of ,(a) providing a phage-displayed synthetic single-chain variable fragment (scFv) library that comprises a plurality of phage-displayed scFvs, wherein the VH domain of each of the plurality of phage-displayed scFvs has a binding affinity to protein A, and the VL domain of each of the plurality of phage-displayed scFvs has a binding affinity to protein L;(b) selecting, from the phage-displayed synthetic scFv library of the step (a), a plurality of phages that express scFvs specific for the protein antigen;(c) preparing a plurality of secreted scFvs respectively from the plurality of phages selected in the step (b);(d) allowing the formation of a plurality of scFv-adaptor-drug complexes by contacting an adaptor-drug conjugate with the plurality of secreted scFvs prepared in the step (c), respectively, wherein the adaptor-drug conjugate comprises a drug and an adaptor that comprises at least one AL module comprising a protein A fragment at the N-terminus and a protein L fragment at the C-terminus;(e) culturing a plurality of cells presenting the protein antigen in the presence of the plurality of scFv-adaptor-drug complexes formed in the step (d), respectively;(f) determining the respective efficacy of the plurality of scFv-adaptor-drug complexes in the plurality of cells presenting the protein antigen cultured in the step (e); and(g) selecting the functional antibody fragment for the immunoconjugate based on the ...

GLYCAN ARRAYS FOR HIGH THROUGHPUT SCREENING OF VIRUSES

Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed. Sandwich assays using gold nanoparticles conjugated to phage particles comprising influenza virus-specific antibodies for detecting multiple serotypes using a single reaction are provided. Plurality of glycans directed to specific target HA of influenza virus comprises the array. Detector molecules comprising noble metals conjugated to (a) phage display particles expressing antibodies against hemagglutinin and (b) neuraminidase binding agents are disclosed. 149-. (canceled)50. An array , comprising:a) a substrate having at least one type of glycan capture probe bound at a discrete location on the substrate, wherein the capture probes can bind to a specific influenza serotype target;b) one or more viruses comprising a specific influenza serotype bound to the corresponding glycan capture probe for the one or more viruses comprising a specific influenza serotype;c) at least one type of nanoparticle probe conjugated to a detector moiety, wherein the detector moiety is bound to the specific influenza serotype;wherein the at least one type of glycan capture probe, the one or more viruses comprising a specific influenza serotype, and the nanoparticle probe form a complex at the discrete location on the substrate, andwherein the nanoparticle comprises a noble metal.51. The array of claim 50 , wherein the influenza serotype is selected from the group consisting of influenza A claim 50 , influenza B claim 50 , influenza A serotypes H1N1 claim 50 , H2N2 claim 50 , H3N1 claim 50 , H3N2 claim 50 , H5N1 claim 50 , H7N7 claim 50 , H1N2 claim 50 , H9N2 claim 50 , H7N2 claim 50 , H7N3 claim 50 , and H10N7.52. The array of claim 50 , wherein the substrate comprises an array of a plurality of glycan capture probes that bind specifically to a plurality of different ...

A phage-displayed single-chain variable fragment library

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1 ) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

Phage displaying system expressing single chain antibody

Methods of treating neurodegenerative diseases

Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.

Recombinant antibodies, kits comprising the same, and uses thereof in diagnosing african swine fever virus

Disclosed herein are recombinant antibodies or the fragments comprising a light chain variable (VL) domain and a heavy chain variable (VH domain) thereof for detecting African swine fever virus (ASFV). Also disclosed herein are kits comprising the recombinant antibodies, and methods of diagnosing the infection of ASFV by using the recombinant antibody or kit.

Recombinant antibodies, kits comprising the same, and uses thereof in diagnosing influenza virus

Disclosed herein are recombinant antibodies or the fragments thereof for detecting influenza A virus (IAV) or influenza B virus (IBV). Also disclosed herein are kits comprising the recombinant antibodies, and methods of making a diagnosis of the infection of IAV or IBV by using the recombinant antibody or kit.

Anti-siglec-3 antibodies, pharmaceutical compositions comprising the same, and uses thereof

Disclosed herein is generally directed to antibodies against the Siglec-3, and pharmaceutical compositions that comprise the antibodies. According to some embodiments of the present disclosure, the present anti-Siglec-3 antibodies may suppress the over activation of Siglec-3, thereby reversing the immunosuppression effects resulted therefrom. As such, the present antibodies may treat diseases associated with the over activation of Siglec-3, such as hepatitis B virus (HBV) infection, neurodegenerative diseases, autoimmune diseases, or cancers. Accordingly, the present disclosure also includes methods for the treatment and/or prophylaxis of the above diseases.

Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof

Disclosed herein are methods for selecting an antibody fragment specific to an influenza virus. According to certain embodiments of the present disclosure, the influenza virus may be influenza virus type A (IAV) or influenza virus type B (IBV). Also disclosed herein are the selected antibodies, recombinant antibody produced from the selected antibodies, and the uses thereof in the diagnosis of influenza virus infection.

Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof

Disclosed herein are methods for selecting an antibody fragment specific to an influenza virus. According to certain embodiments of the present disclosure, the influenza virus may be influenza virus type A (IAV) or influenza virus type B (IBV). Also disclosed herein are the selected antibodies, recombinant antibody produced from the selected antibodies, and the uses thereof in the diagnosis of influenza virus infection.

A phage-displayed single-chain variable fragment library for selecting antibody fragments specific to mesothelin

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized with a specific sequence in each CDR. The present phage-displayed scFv library is useful in selecting an antibody fragment exhibiting a binding affinity and specificity to mesothelin (MSLN). Also disclosed herein are a recombinant antibody specific to MSLN, an immunoconjugate comprising the recombinant antibody, and uses thereof in treating cancers.

Method for high-throughput screening of neutralizing antibodies, neutralizing antibodies produced therefrom, and uses thereof

Disclosed herein are methods for high-throughput screening of a virus-specific neutralizing antibody. According to certain embodiments of the present disclosure, the virus is an influenza virus. Also disclosed herein are the antibodies selected by the high-throughput screening method, and the uses thereof in the prophylaxis and/or treatment of viral infection.

A phage-displayed single-chain variable fragment library for selecting antibody fragments specific to mesothelin

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized with a specific sequence in each CDR. The present phage-displayed scFv library is useful in selecting an antibody fragment exhibiting a binding affinity and specificity to mesothelin (MSLN). Also disclosed herein are a recombinant antibody specific to MSLN, an immunoconjugate comprising the recombinant antibody, and uses thereof in treating cancers.

Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof

A phage-displayed single-chain variable fragment library for selecting antibody fragments specific to mesothelin

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized with a specific sequence in each CDR. The present phage-displayed scFv library is useful in selecting an antibody fragment exhibiting a binding affinity and specificity to mesothelin (MSLN). Also disclosed herein are a recombinant antibody specific to MSLN, an immunoconjugate comprising the recombinant antibody, and uses thereof in treating cancers.

Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof

Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.

Methods of treating neurodegenerative diseases

Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.